The evolving landscape of RAAS inhibition: From ACE inhibitors to ARBs, to DRIs andbeyond

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 6, 2012, Pages 713-725

  Epstein, Benjamin J ^a   Leonard, Paul T ^a   Shah, Niren K ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b East Coast Institute for Research   (United States)

Author keywords

(pro)renin receptor; ACE inhibitor; angiotensin receptor blocker; direct renin inhibitor; plasma renin activity

Indexed keywords

ALBUMIN; ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BRADYKININ; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CAPTOPRIL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; PLACEBO; RAMIPRIL; RENIN INHIBITOR; SPIRONOLACTONE; TELMISARTAN; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CREATININE URINE LEVEL; DIABETES MELLITUS; DISEASE SEVERITY; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; IN VITRO STUDY; JUXTAGLOMERULAR CELL; KIDNEY DISEASE; KIDNEY FUNCTION; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; SUDDEN DEATH; SYNCOPE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPREGULATION;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; KIDNEY DISEASES; RENIN; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 84865259797     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.63     Document Type: Review

References (53)

1. Tigerstedt R, Bergman PG. Niere und Kreislauf. Skand. Arch. Physiol. 8, 223-271 (1898).
2. Atlas SA. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J. Manag. Care Pharm. 13(8 Suppl. B), 9-20 (2007).
3. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension: I. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J. Exp. Med. 59(3), 347-379 (1934).
4. Dzau VJ. Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37(4), 1047-1052 (2001).
5. Sureshkumar KK. Renin inhibition with aliskiren in hypertension: focus on aliskiren/hydrochlorothiazide combination therapy. Vasc. Health Risk Manag. 4(6), 1205-1220 (2008).
6. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342, 145-153 (2000).
7. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N. Engl. J. Med. 327, 685-691 (1992).
8. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342, 821-828 (1993).
9. Køber L, Torp-Pedersen C, Carlsen JE et al. A clinical trial of the angiotensin converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med. 333(25), 1670-1676 (1995).
10. Rutherford JD, Pfeffer MA, Moyé LA et al. Effects of captopril on ischemic events after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. SAVE Investigators. Circulation 90(4), 1731-1738 (1994).
11. Fox KM; European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362(9386), 782-788 (2003).
12. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators. Aliskiren combined with losartan in Type 2 diabetes and nephropathy. N. Engl. J. Med. 358(23), 2433-2446 (2008).
13. Brenner BM, Cooper ME, de Zeeuw D et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N. Engl. J. Med. 345(12), 861-869 (2001).
14. Lewis EJ, Hunsicker LG, Clarke WR et al.; Collaborative Study Group. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N. Engl. J. Med. 345(12), 851-860 (2001).
15. Roger VL, Go AS, Lloyd-Jones DM et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 123(4), e18-e209 (2011).
16. Nguyen G, Delarue F, Burcklé C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in Ang II production and cellular responses to renin. J. Clin. Invest. 109(11), 1417-1427 (2002).
17. Bindom SM, Lazartigues E. The sweeter side of ACE2: physiological evidence for a role in diabetes. Mol. Cell. Endocrinol. 302(2), 193-202 (2009).
18. Hollenberg NK, Fisher ND, Price DA. Pathways for Ang II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system. Hypertension 32(3), 387-392 (1998).
19. Watanabe T, Barker TA, Berk BC. Ang II and the endothelium: diverse signals and effects. Hypertension 45(2), 163-169 (2005).
20. Numaguchi Y, Ishii M, Kubota R et al. Ablation of Ang IV receptor attenuates hypofibrinolysis via PAI-1 downregulation and reduces occlusive arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 29(12), 2102-2108 (2009).
21. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. Human homolog of ang converting enzyme. Cloning and functional expression as captopril insensitive carboxypeptidase. J. Biol. Chem. 275, 33238-33243 (2000).
22. Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D. Glomerular localization and expression of angiotensin converting enzyme 2 and angiotensin converting enzyme: implications for albuminuria in diabetes. J. Am. Soc. Nephrol. 17(11), 3067-3075 (2006).
23. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Ang II suppression in humans by the orally active renin inhibitor aliskiren (SPP100): comparison with enalapril. Hypertension 39(1), E1-E8 (2002).
24. Biswas KB, Nabi AH, Arai Y et al. Aliskiren binds to renin and prorenin bound to (pro)renin receptor in vitro. Hypertens. Res. 33(10), 1053-1059 (2010).
25. Schefe JH, Neumann C, Goebel M et al. Prorenin engages the (pro)renin receptor like renin and both ligand activities are unopposed by aliskiren. J. Hypertens. 26(9), 1787-1794 (2008).
26. Feldman DL, Jin L, Xuan H et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52(1), 130-136 (2008).
27. CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. 316, 1429-1435 (1987).
28. Pfeffer MA, Braunwald E, Moyé LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 327(10), 669-677 (1992).
29. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin convertingenzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N. Engl. J. Med. 329(20), 1456-1462 (1993).
30. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension 38(6), E28-E32 (2001).
31. Jorde UP, Ennezat PV, Lisker J et al. Maximally recommended doses of angiotensin converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of Ang II in chronic heart failure. Circulation 101(8), 844-846 (2000).
32. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. 345(23), 1667-1675 (2001).
33. Yusuf S, Teo K, Anderson C et al.; Telmisartan Randomised Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (TRANSCEND) Investigators. Effects of the angiotensin receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin converting enzyme inhibitors: a randomised controlled trial. Lancet 372(9644), 1174-1183 (2008).
34. Dahlöf B, Devereux RB, Kjeldsen SE et al.; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet 359(9311), 995-1003 (2002).
35. Granger CB, McMurray JJ, Yusuf S et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362(9386), 772-776 (2003).
36. Puig JG, Schunkert H, Taylor AA, Boye S, Jin J, Keefe DL. Evaluation of the dose-response relationship of aliskiren, a direct renin inhibitor, in an 8-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled study in adult patients with stage 1 or 2 essential hypertension. Clin. Ther. 31(12), 2839-2850 (2009).
37. Schmieder RE, Philipp T, Guerediaga J et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 119(3), 417-425 (2009).
38. Solomon SD, Appelbaum E, Manning WJ et al.; Aliskiren in Left Ventricular Hypertrophy (ALLAY) Trial Investigators. Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 119(4), 530-537 (2009).
39. Solomon SD, Shin SH, Shah A et al.; Aliskiren Study in Post-MI Patients to Reduce Remodeling (ASPIRE) Investigators. Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur. Heart J. 32(10), 1227-1234 (2011).
40. McMurray JJ, Pitt B, Latini R et al.; Aliskiren Observation of Heart Failure Treatment (ALOFT) Investigators. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ. Heart Fail. 1(1), 17-24 (2008).
41. Pimenta E, Oparil S. Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Vasc. Health Risk Manag. 5(1), 453-463 (2009).
42. Pfeffer MA, McMurray JJ, Velazquez EJ et al.; Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 349(20), 1893-1906 (2003).
43. McMurray JJ, Ostergren J, Swedberg K et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362(9386), 767-771 (2003).
44. Yusuf S, Teo KK, Pogue J et al.; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 358(15), 1547-1559 (2008).
45. Parving HH, Brenner BM, McMurray JJ et al. Aliskiren trial in Type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 24(5), 1663-1671 (2009).
46. Chobanian AV, Bakris GL, Black HR et al.; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289(19), 2560-2572 (2003).
47. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981-2997 (2002).
48. White WB, Murwin D, Chrysant SG, Koval SE, Davidai G, Guthrie R. Effects of the Ang II receptor blockers telmisartan versus valsartan in combination with hydrochlorothiazide: a large, confirmatory trial. Blood Press. Monit. 13(1), 21-27 (2008).
49. Lacourcière Y, Neutel JM, Schumacher H. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials. Clin. Ther. 27(11), 1795-1805 (2005).
50. Smith TR, Philipp T, Vaisse B et al. Amlodipine and valsartan combined and as monotherapy in stage 2, elderly, and black hypertensive patients: subgroup analyses of randomized, placebo-controlled studies. J. Clin. Hypertens. (Greenwich). 9(5), 355-364 (2007).
51. Dahlöf B, Sever PS, Poulter NR et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366(9489), 895-906 (2005).
52. Jamerson K, Weber MA, Bakris GL et al.; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 359(23), 2417-2428 (2008).
53. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of Ang-II receptor blocker and angiotensin converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361(9352), 117-124 (2003).